Treatment of hip pain with sustained-release liposomal anesthetic compositions
In some embodiments provided herein is a method of treating hip pain in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.
1. A method of treating hip pain in a subject, the method comprising administering to the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome,
wherein the pharmaceutical composition is administered by a needle injection, wherein a needle tip is located at a distal end of the injection needle and
injecting the composition occurs while a distal portion of the needle is aligned with the anterior inferior iliac spine (AIIS) and proximate the AIIS and positioned lateral to the psoas tendon between the AIIS and psoas tendon, and wherein the needle tip is spaced away from a musculofascial plane between the psoas tendon and the pubic ramus.
2. The method of claim 1 , wherein the aqueous phase further comprises hydrochloric acid.
3. The method of claim 1 , wherein the amphipathic lipid is selected from the group consisting of phosphatidylcholines, phosphatidylethanolamines, sphingomyelins, lysophosphatidylcholines, lysophosphatidylethanolamines, phosphatidylglycerols, phosphatidylserines, phosphatidylinositols, phosphatidic acids, cardiolipins, diacyl dimethylammonium propanes, and stearylamines.
4. The method of claim 1 , wherein the neutral lipid is at least one triglyceride.
5. The method of claim 1 , wherein the pharmaceutical composition comprises a therapeutically effective amount of bupivacaine phosphate.
6. The method of claim 5 , wherein the pharmaceutical composition comprises bupivacaine phosphate in an amount equivalent to from about 20 mg to about 300 mg of bupivacaine.
7. The method of claim 6 , wherein the pharmaceutical composition comprises bupivacaine phosphate in an amount equivalent to from about 133 mg to about 266 mg of bupivacaine.
8. The method of claim 1 , wherein the pharmaceutical composition is administered following completion of a hip treatment.
9. The method of claim 1 , wherein the method does not comprise administering an opioid to the subject following completion of the treatment.
10. The method of claim 1 , wherein the method comprises administering an opioid to the subject following completion of the treatment.
11. The method of claim 10 , wherein the method comprises administering to the subject following completion of the treatment an amount of an opioid selected from the group consisting of: less than 200 mg, less than 100 mg, less than 50 mg, and less than 25 mg.
12. The method of claim 11 , wherein the opioid is oxycodone and the method comprises administering oxycodone in a total amount less than or equal to 10 mg or administering morphine in a total amount less than or equal to 15 mg in the first about 72 hours following completion of the treatment.
13. The method of claim 8 , wherein the method comprises administering a non-opioid analgesic to the subject following completion of the treatment.
14. The method of claim 1 , wherein the subject has an AUC for VAS pain intensity scores over the first 72 hours following completion of the treatment selected from the group consisting of about 100 to about 200, about 125 to 175, about 140 to 160, about 150, and about 147.9.
15. The method of claim 1 , wherein the subject has a distress from itchiness score as determined by the OBAS scale selected from the group consisting of less than 4, 0, 1, 2, and 3.
16. The method of claim 1 , wherein the plasma concentration of bupivacaine in the subject after about 120 hours following completion of the treatment is about 150 ng/mL to about 250 ng/mL, for an amount of the pharmaceutical composition described herein that is equivalent to about 133 mg of bupivacaine.
17. The method of claim 1 , wherein the needle has a needle length between 60 mm and 150 mm.
18. The method of claim 17 , wherein the needle has a diameter between 25 gauge and 20 gauge.
19. The method of claim 1 , wherein administration comprises advancing the needle using an in-plane mode of insertion relative to an imaging transducer.
20. The method of claim 1 , wherein administration comprises advancing the needle tip from a lateral-to-medial direction.
21. The method of claim 20 , wherein administration comprises advancing the needle tip along a cephalad-to-caudad and lateral-to-medial trajectory.
22. The method of claim 1 , wherein injecting the composition occurs while the needle is parallel with the anterior inferior iliac spine proximate the needle tip.
23. The method of claim 16 , wherein the plasma concentration of bupivacaine is from about 175 ng/mL to about 225 ng/mL.
24. The method of claim 1 , wherein the needle tip is located medial of the slope of the anterior inferior iliac spine and lateral to the psoas tendon.
25. The method of claim 1 , wherein the needle tip is within 15 degrees of exactly parallel of the anterior inferior iliac spine.
26. The method of claim 25 , wherein the pharmaceutical composition is administered before hip surgery.
27. The method of claim 1 , wherein administering the composition includes advancing the needle tip of the injection needle from a subject access location proximate the inguinal crease along a cephalad-to-caudad and lateral-to-medial trajectory.